The therapeutic application of Progestérone Biogaran (micronized progesterone) is commonly used in situations involving certain distressing symptoms linked to progesterone deficiency. The medication is generally applied across domains where additional symptomatic support is needed for specific gynecological and reproductive conditions.

Progesterone supplementation is relevant in contexts marked by increased discomfort or tension, addressing conditions such as Endometrial Protection during HRT, secondary amenorrhea (absent periods), luteal phase deficiencies in fertility, and the neuro-vegetative symptoms of the menopausal transition. It helps address symptom clusters that may become disruptive, such as sleep disturbances, mood instability, and hot flashes.

---

Key Therapeutic Support

This medication supports general well-being during symptomatic phases, providing support that helps ease the overall symptom burden linked to systemic imbalance. It is considered relevant for easing symptoms that interfere with daily comfort.

“This supportive approach assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Sleep Disturbances Progesterone supplementation may assist with maintaining functional stability by easing symptoms related to systemic imbalance, such as insomnia and anxiety.

Regulatory References

1. Progesterone: MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Progestérone Biogaran — official regulatory information

Scope Element	Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adult women requiring progesterone supplementation for approved conditions (e.g., endometrial protection during HRT, luteal phase support, secondary amenorrhea).
Populations for whom use is not recommended (if applicable)	Pregnant women beyond the first trimester (use is contraindicated); women who are breastfeeding.
Populations for whom use is contraindicated	Patients with known hypersensitivity to progesterone, peanut, or soy; a history of breast cancer or other hormone-dependent malignancies; active thromboembolic disorders (e.g., DVT, PE); severe liver disease; or undiagnosed abnormal genital bleeding.
Age-related eligibility rules	Pediatric Use is not indicated and safety is not established. Geriatric use has no specific problems documented, but caution is necessary due to baseline risks associated with this age group.
Condition-specific eligibility rules	Severe liver dysfunction is a formal contraindication. Mild to moderate hepatic impairment and renal impairment require careful monitoring and caution.
Pregnancy and lactation eligibility status (if explicitly documented)	Permitted only during the first trimester for approved indications. Contraindicated from the 4th month (beyond the first trimester). Not recommended during lactation.
Eligibility-related restrictions	Caution required for patients with conditions that may be aggravated by fluid retention (e.g., hypertension, cardiac disease) and those with a history of migraines or depression.

---

Eligibility classifications (high-level)

Classification Element	Statement
Eligibility severity classification (as defined in official documents)	Contraindicated (e.g., severe liver disease, DVT); Not Indicated (e.g., pediatric use); Not Recommended (e.g., lactation); Requires Caution/Monitoring (e.g., mild hepatic impairment).
Regulatory basis (EMA / FDA / etc.)	Based on official governmental prescribing information.
Eligibility-context constraints (as defined in official documents)	Contraindications are based on specific organ function (hepatic), disease history (thrombosis, cancer), and developmental stage (second/third trimester pregnancy).

---

Resulting eligibility structure

Official eligibility statements:

• Use is contraindicated in patients with a history of or active thromboembolic disorders (DVT, PE).
• The medicine is contraindicated for patients with severe liver disease or known hypersensitivity to peanut or soy (due to excipients).
• Progestérone Biogaran is not indicated and safety is not established for use in the pediatric population.
• Use is strictly limited to the first trimester of pregnancy for approved indications, and contraindicated from the fourth month.
• Patients with mild to moderate hepatic impairment or renal impairment require caution and close monitoring during use.
• The medicine is contraindicated for women with known or suspected hormone-dependent malignancies, such as breast cancer.

Connection to the overall eligibility profile Regulatory documents define who can and cannot use Progestérone Biogaran by establishing clear absolute contraindications linked to major vascular events, severe organ dysfunction, and certain cancers. Eligibility is further structured by age limitations, specifically prohibiting use in the pediatric population, and by pregnancy restrictions, which limit use to the early stages for specific conditions and prohibit it thereafter. Conditional eligibility requires that individuals with impaired renal or mild hepatic function, or specific cardiovascular issues, use the medicine only with close monitoring.

Interactions with other medicines and products

It is essential to inform your doctor or pharmacist about all other medicines, over-the-counter drugs, and herbal supplements you are currently taking or have recently taken. Progesterone can interact with various substances, which may affect its efficacy or increase the risk of side effects.

---

Enzyme-Inducing Medicines

Certain medicines can decrease the level of Progestérone Biogaran in the blood by speeding up its metabolism in the liver. This can make the treatment less effective. Examples include:

• Epilepsy medicines: Phenytoin, carbamazepine, phenobarbital.
• Tuberculosis medicines: Rifampicin, rifabutin.
• HIV medicines: Ritonavir, nelfinavir, efavirenz.
• Other: Bosentan (for pulmonary hypertension).

Enzyme-Inhibiting Medicines

Conversely, some drugs can increase the concentration of Progestérone Biogaran in the blood by slowing down its breakdown, potentially increasing the risk of adverse effects, such as drowsiness. Examples include:

• Antifungal medicines: Ketoconazole, itraconazole.
• Certain antibiotics: Clarithromycin.

---

Other Interactions

• Ciclosporin: Progesterone may increase the blood levels of this immunosuppressant drug.
• Medicines that increase drowsiness: Progesterone itself can cause drowsiness; taking it with other sedating agents (e.g., alcohol, anxiolytics) may intensify this effect, making activities like driving unsafe.
• Herbal products: The herbal remedy St. John’s Wort can reduce the effectiveness of progesterone and should be avoided.

Always consult your healthcare provider for personalized advice on managing potential drug interactions.

Progesterone Receptor Activation and Genomic Action

This drug is a form of micronized progesterone that functions as an agonist by binding to and activating the intracellular Progesterone Receptors (PR) found in various cells. This interaction triggers genomic signaling, where the activated receptor complex enters the cell nucleus to alter the transcription of specific target genes, thereby modulating long-term cellular function.

Modulating Uterine Endometrial Transformation

In the uterus, PR activation guides the lining (endometrium) through a process of secretory transformation, shifting the tissue from a growth phase into a highly specialized structure. This physiological change affects the reproductive system's internal tissue dynamics.

Central Nervous System Feedback and Thermoregulation

Systemically, the drug's presence influences the central regulatory systems. It exerts negative feedback on the Hypothalamic-Pituitary-Gonadal (HPG) axis, modulating the release of pituitary hormones. Furthermore, interaction with receptors in the brain's thermoregulatory center leads to an elevation in basal body temperature and contributes to CNS-mediated modulation of neuronal activity.

How Progestérone Biogaran is Used

Progestérone Biogaran (micronized progesterone) is administered according to schedules that determine the route, timing, and duration of use. The medication is formulated as a soft capsule available in 100 mg and 200 mg strengths.

---

Approved Administration Routes and Timing

The soft capsule is approved for administration via the oral route (swallowing) or the vaginal route (insertion). The route is selected based on the specific condition and patient tolerance.

For oral use, the dose is typically taken at bedtime and ideally at a distance from meals. This timing is intended to standardize the administration procedure. If a dose is missed by more than three hours, the common practice is to skip the missed dose and resume the regular schedule.

---

Dosing Patterns and Schedules

Usage patterns are generally defined by either cyclic or continuous administration. In Hormone Replacement Therapy (HRT), cyclic use commonly involves taking 200 mg once daily for 10 to 14 days per month (sequential regimen). Continuous combined HRT typically utilizes a dose of 100 mg per day, taken every day.

For certain reproductive indications, the daily dose, administered vaginally, may reach a maximum of 600 mg per day, often administered in three divided doses. Use is generally not recommended in pre-pubescent children.

Research evidence / Overview of studies for Progestérone Biogaran

---

Evidence for Use in Endometrial Protection during HRT

The research base for this indication is built on both large, long-term observational cohort studies and randomized controlled trials (RCTs). These studies examined the research question regarding endometrial protection in postmenopausal women who are also receiving estrogen therapy. Researchers primarily monitored the health of the uterine lining over several years, using histological assessments to measure the absence of cellular changes that could lead to hyperplasia or carcinoma (cancer).

The findings describe patterns observed in the studies where this type of progesterone was observed in regimes designed to provide counter-balance against estrogen's effects on the endometrium. However, the definitive long-term data concerning potential associated cancer risk are largely derived from observational cohort studies, rather than head-to-head RCTs. Therefore, there is limited information for long-term outcomes regarding relative risks in all contexts, and the long-term evidence base is under continuous observation.

---

Evidence for Measured Symptom Changes in Menopause

Studies have explored how the medication was studied for outcomes related to physical discomfort and systemic or functional imbalance during the menopausal transition. The research involves randomized controlled trials to examine patient-reported experiences, monitoring outcomes related to sleep quality, mood stability, and the frequency and intensity of vasomotor symptoms like hot flashes.

The research highlights changes measured during the study period across these symptom axes. Certainty remains low for some aspects of symptom control, as the findings were mixed regarding the medication’s effects on certain mood states. Furthermore, the follow-up durations were limited (often short-term, around 3 to 12 months) in the RCTs focusing on these fluctuating or episodic symptom patterns.

---

What is Still Uncertain About Progestérone Biogaran Research

Evidence highlights what is known — and what is still uncertain. Key limitations include comparative evidence is lacking against all forms of progestins for long-term outcomes like breast health, which relies heavily on observational data. For symptom management, findings were mixed across various studies, suggesting that the measured results may not be universally consistent. Studies focusing on acute outcomes, such as inducing withdrawal bleeding, have follow-up durations were limited by design, meaning the research does not determine whether an individual will respond similarly over extended periods.

Key Studies & References

1. Progestogens and endometrial protection - British Menopause Society (BMS) Tool for clinicians
2. Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses – Frontiers in Endocrinology

Common questions about Progestérone Biogaran (FAQ)

---

Q: Is Progestérone Biogaran the same as natural progesterone?

Official documentation indicates that Progestérone Biogaran is a form of micronized progesterone. The active substance is chemically identical to the progesterone hormone naturally produced by the human body. Although chemically the same, the medication is synthesized from plant-sourced starting materials under regulated laboratory conditions.

---

Q: Is it common to feel tired or dizzy after taking Progestérone Biogaran?

Yes, somnolence (drowsiness) and dizziness are listed in the official safety profile as common adverse effects. These effects are often more noticeable at the beginning of oral treatment. Regulatory information describes that the oral dose is instructed to be taken at bedtime, which is intended to help reduce the impact of these effects during the day.

---

Q: How long does it typically take for Progestérone Biogaran to start working?

Pharmacokinetic studies show that the highest concentration of the active ingredient in the blood is typically reached within 1 to 3 hours after taking the oral capsule. However, the full clinical effects of the medication involve genomic signaling and cellular modulation, which develop gradually over the entire prescribed treatment cycle.

---

Q: Does Progestérone Biogaran affect mood or emotions?

Regulatory documents list mood swings and depression in the adverse reactions profile. Official warnings state that patients with a history of psychic depression require careful observation and that discontinuation of the drug may be necessary if the depression recurs to a serious degree.

---

Q: Can Progestérone Biogaran affect sleep?

Yes, somnolence (drowsiness) is documented as a common adverse reaction, especially with oral administration. Due to this effect, official instructions advise that the medication be taken at bedtime, as the side effect profile suggests it can influence the natural sleep/wake cycle.

---

Q: Is it important to take Progestérone Biogaran with food?

Official instructions specify that the oral dose should be taken at a distance from meals and only at bedtime. This administration instruction is based on evidence related to how food affects the absorption of the medication.

---

Q: Can men use Progestérone Biogaran for any reason?

Official regulatory documents define the therapeutic indications primarily for adult women requiring progesterone supplementation for conditions such as luteal phase support or endometrial protection during Hormone Replacement Therapy (HRT). No indications for use in men are described in the official product information.

---

Q: What happens when you stop taking Progestérone Biogaran?

In certain cyclic treatment regimens, a planned stop in the dosage schedule is expected to trigger a withdrawal bleed (similar to a menstrual period). When treatment ends, the hormonal effects of the drug on the body will slowly decrease as the medicine is naturally eliminated.

---

Q: What is the role of progesterone in the female body?

Official information describes the purpose of the medicine as addressing problems linked to a progesterone deficit. The hormone's natural role is crucial for establishing and maintaining hormonal equilibrium, especially through its gestagenic effect on the uterine lining and its regulation of the menstrual cycle.

---

Q: Does Progestérone Biogaran affect blood pressure?

Regulatory warnings require caution for patients with conditions like hypertension (high blood pressure) or cardiac disease that could be aggravated by fluid retention. The medication also has known anti-aldosterone properties, which means it may indirectly influence blood pressure by affecting fluid balance.

---

Q: Can I travel while using Progestérone Biogaran?

Due to the potential for common side effects like drowsiness and dizziness, official warnings caution against driving a vehicle or operating machinery. The official safety warning related to these side effects is designed to inform users about the potential impact on operating certain types of transport during travel.

---

Q: What does Biogaran mean in the drug name?

Biogaran is the name of the laboratory (manufacturer) that produces this medicine. This label signifies that the product is a generic version of the reference progesterone medication, approved to be therapeutically equivalent.

---

Q: Is Progestérone Biogaran used to treat polycystic ovary syndrome (PCOS)?

Official indications for this medication include treating irregularities of the menstrual cycle and secondary amenorrhea (lack of periods), which are symptoms often associated with Polycystic Ovary Syndrome (PCOS). The drug is used to address the underlying progesterone deficiency in these specific circumstances.

---

Q: Are there any known long-term risks with Progestérone Biogaran use?

When used in combination with estrogen for Hormone Replacement Therapy (HRT), the regulatory documents describe an increased risk of thromboembolic events (blood clots) and mention the potential for a small increase in the risk of breast cancer (as noted by observational data).

---

Q: What is the difference between Progestérone Biogaran and synthetic progestins?

Progestérone Biogaran is a form of natural progesterone, meaning the hormone is chemically identical to the one produced by the human body. This is distinct from synthetic progestins, which are man-made chemicals designed to mimic progesterone's action but have a different chemical structure and may have different effects.

---

Q: Does Progestérone Biogaran cause a period (withdrawal bleed)?

Yes, if the medication is prescribed in a cyclic regimen (meaning you take it for a period and then stop), the planned break in treatment is typically expected to trigger a withdrawal bleed, which is similar to a menstrual period. If the period does not occur, official documents suggest medical evaluation is necessary.

---

Q: Are headaches a known side effect of Progestérone Biogaran?

Yes, headache is explicitly listed in the official safety profile as a common adverse effect of the medication. Other common effects include drowsiness, abdominal discomfort, and breast pain.

---

Q: How is Progestérone Biogaran eliminated from the body?

According to pharmacokinetic data, the active ingredient is first processed and broken down (metabolized) primarily in the liver. It is then eliminated from the body mostly through the urine in the form of inactive substances called metabolites.

How to Store and Dispose of Progestérone Biogaran

Official regulatory information states that this medication requires no special storage precautions regarding temperature or light protection. The product should be kept in its original packaging and must not be used after the expiration date indicated on the box. Additionally, do not use the capsules if you observe any visible signs of deterioration.

---

Handling and Child Safety

It is essential to keep Progestérone Biogaran out of the sight and reach of children at all times.

---

Disposal Requirements

For proper disposal, regulatory guidelines strictly prohibit discarding unused or expired medication in household trash or flushing it down a toilet or drain (wastewater). To protect the environment, any unused medicine must be returned to a pharmacist for safe and appropriate elimination.